1
|
Li M, Konteatis Z, Nagaraja N, Chen Y, Zhou S, Ma G, Gross S, Marjon K, Hyer ML, Mandley E, Lein M, Padyana AK, Jin L, Tong S, Peters R, Murtie J, Travins J, Medeiros M, Liu P, Frank V, Judd ET, Biller SA, Marks KM, Sui Z, Reznik SK. Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads. J Med Chem 2022; 65:4600-4615. [PMID: 35293760 DOI: 10.1021/acs.jmedchem.1c01595] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Inhibition of the S-adenosyl methionine (SAM)-producing metabolic enzyme, methionine adenosyltransferase 2A (MAT2A), has received significant interest in the field of medicinal chemistry due to its implication as a synthetic lethal target in cancers with the deletion of the methylthioadenosine phosphorylase (MTAP) gene. Here, we report the identification of novel MAT2A inhibitors with distinct in vivo properties that may enhance their utility in treating patients. Following a high-throughput screening, we successfully applied the structure-based design lessons from our first-in-class MAT2A inhibitor, AG-270, to rapidly redesign and optimize our initial hit into two new lead compounds: a brain-penetrant compound, AGI-41998, and a potent, but limited brain-penetrant compound, AGI-43192. We hope that the identification and first disclosure of brain-penetrant MAT2A inhibitors will create new opportunities to explore the potential therapeutic effects of SAM modulation in the central nervous system (CNS).
Collapse
Affiliation(s)
- Mingzong Li
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Zenon Konteatis
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Nelamangala Nagaraja
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Yue Chen
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Shubao Zhou
- PharmaResources Co., Ltd., 509 Renqing Road, Pudong New Area, Shanghai 201201, China
| | - Guangning Ma
- PharmaResources Co., Ltd., 509 Renqing Road, Pudong New Area, Shanghai 201201, China
| | - Stefan Gross
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Katya Marjon
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Marc L Hyer
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Everton Mandley
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Max Lein
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Anil K Padyana
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Lei Jin
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Shuilong Tong
- Viva Biotech, Ltd., 334 Aidisheng Road, Zhangjiang High-Tech Park, Shanghai 201203, China
| | - Rachel Peters
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Joshua Murtie
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Jeremy Travins
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Matthew Medeiros
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Peng Liu
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Victoria Frank
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Evan T Judd
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Scott A Biller
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Kevin M Marks
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Zhihua Sui
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Samuel K Reznik
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
2
|
Konteatis Z, Travins J, Gross S, Marjon K, Barnett A, Mandley E, Nicolay B, Nagaraja R, Chen Y, Sun Y, Liu Z, Yu J, Ye Z, Jiang F, Wei W, Fang C, Gao Y, Kalev P, Hyer ML, DeLaBarre B, Jin L, Padyana AK, Dang L, Murtie J, Biller SA, Sui Z, Marks KM. Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion. J Med Chem 2021; 64:4430-4449. [PMID: 33829783 DOI: 10.1021/acs.jmedchem.0c01895] [Citation(s) in RCA: 33] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The metabolic enzyme methionine adenosyltransferase 2A (MAT2A) was recently implicated as a synthetic lethal target in cancers with deletion of the methylthioadenosine phosphorylase (MTAP) gene, which is adjacent to the CDKN2A tumor suppressor and codeleted with CDKN2A in approximately 15% of all cancers. Previous attempts to target MAT2A with small-molecule inhibitors identified cellular adaptations that blunted their efficacy. Here, we report the discovery of highly potent, selective, orally bioavailable MAT2A inhibitors that overcome these challenges. Fragment screening followed by iterative structure-guided design enabled >10 000-fold improvement in potency of a family of allosteric MAT2A inhibitors that are substrate noncompetitive and inhibit release of the product, S-adenosyl methionine (SAM), from the enzyme's active site. We demonstrate that potent MAT2A inhibitors substantially reduce SAM levels in cancer cells and selectively block proliferation of MTAP-null cells both in tissue culture and xenograft tumors. These data supported progressing AG-270 into current clinical studies (ClinicalTrials.gov NCT03435250).
Collapse
Affiliation(s)
- Zenon Konteatis
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Jeremy Travins
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Stefan Gross
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Katya Marjon
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Amelia Barnett
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Everton Mandley
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Brandon Nicolay
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Raj Nagaraja
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Yue Chen
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Yabo Sun
- Viva Biotech, Shanghai 201203, China
| | | | - Jie Yu
- Viva Biotech, Shanghai 201203, China
| | | | - Fan Jiang
- Viva Biotech, Shanghai 201203, China
| | | | | | - Yi Gao
- ChemPartner, Shanghai 201203, China
| | - Peter Kalev
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Marc L Hyer
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Byron DeLaBarre
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Lei Jin
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Anil K Padyana
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Lenny Dang
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Joshua Murtie
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Scott A Biller
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Zhihua Sui
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| | - Kevin M Marks
- Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, Massachusetts 02139, United States
| |
Collapse
|
3
|
Kalev P, Hyer ML, Gross S, Konteatis Z, Chen CC, Fletcher M, Lein M, Aguado-Fraile E, Frank V, Barnett A, Mandley E, Goldford J, Chen Y, Sellers K, Hayes S, Lizotte K, Quang P, Tuncay Y, Clasquin M, Peters R, Weier J, Simone E, Murtie J, Liu W, Nagaraja R, Dang L, Sui Z, Biller SA, Travins J, Marks KM, Marjon K. MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage. Cancer Cell 2021; 39:209-224.e11. [PMID: 33450196 DOI: 10.1016/j.ccell.2020.12.010] [Citation(s) in RCA: 78] [Impact Index Per Article: 26.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/11/2020] [Revised: 10/30/2020] [Accepted: 12/10/2020] [Indexed: 12/13/2022]
Abstract
The methylthioadenosine phosphorylase (MTAP) gene is located adjacent to the cyclin-dependent kinase inhibitor 2A (CDKN2A) tumor-suppressor gene and is co-deleted with CDKN2A in approximately 15% of all cancers. This co-deletion leads to aggressive tumors with poor prognosis that lack effective, molecularly targeted therapies. The metabolic enzyme methionine adenosyltransferase 2α (MAT2A) was identified as a synthetic lethal target in MTAP-deleted cancers. We report the characterization of potent MAT2A inhibitors that substantially reduce levels of S-adenosylmethionine (SAM) and demonstrate antiproliferative activity in MTAP-deleted cancer cells and tumors. Using RNA sequencing and proteomics, we demonstrate that MAT2A inhibition is mechanistically linked to reduced protein arginine methyltransferase 5 (PRMT5) activity and splicing perturbations. We further show that DNA damage and mitotic defects ensue upon MAT2A inhibition in HCT116 MTAP-/- cells, providing a rationale for combining the MAT2A clinical candidate AG-270 with antimitotic taxanes.
Collapse
Affiliation(s)
- Peter Kalev
- Biology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Marc L Hyer
- Pharmacology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Stefan Gross
- Biochemistry and Biophysics, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Zenon Konteatis
- Chemistry, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Chi-Chao Chen
- Bioinformatics, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Mark Fletcher
- Bioinformatics, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Max Lein
- Drug Metabolism and Pharmacokinetics, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Elia Aguado-Fraile
- Clinical Biomarkers, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Victoria Frank
- Biology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Amelia Barnett
- Biology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Everton Mandley
- Pharmacology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Joshua Goldford
- Cell Metabolism, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Yue Chen
- Drug Metabolism and Pharmacokinetics, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Katie Sellers
- Cell Metabolism, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Sebastian Hayes
- Cell Metabolism, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Kate Lizotte
- Cell Metabolism, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Phong Quang
- Biology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Yesim Tuncay
- Biology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Michelle Clasquin
- Cell Metabolism, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Rachel Peters
- Toxicology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Jaclyn Weier
- Biology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Eric Simone
- Chemistry, Manufacturing and Control, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Joshua Murtie
- Biology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA; Pharmacology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Wei Liu
- Bioinformatics, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Raj Nagaraja
- Drug Metabolism and Pharmacokinetics, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Lenny Dang
- Biochemistry and Biophysics, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Zhihua Sui
- Chemistry, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Scott A Biller
- Chemistry, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Jeremy Travins
- Chemistry, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Kevin M Marks
- Biology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA
| | - Katya Marjon
- Biology, Agios Pharmaceuticals, Inc., Cambridge, MA 02139, USA.
| |
Collapse
|
4
|
Liu H, Niu D, Tham Sjin RT, Dubrovskiy A, Zhu Z, McDonald JJ, Fahnoe K, Wang Z, Munson M, Scholte A, Barrague M, Fitzgerald M, Liu J, Kothe M, Sun F, Murtie J, Ge J, Rocnik J, Harvey D, Ospina B, Perron K, Zheng G, Shehu E, D’Agostino LA. Discovery of Selective, Covalent FGFR4 Inhibitors with Antitumor Activity in Models of Hepatocellular Carcinoma. ACS Med Chem Lett 2020; 11:1899-1904. [PMID: 33062171 DOI: 10.1021/acsmedchemlett.9b00601] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2019] [Accepted: 03/06/2020] [Indexed: 12/28/2022] Open
Abstract
Hepatocellular carcinoma (HCC) accounts for a majority of primary liver cancer and is one of the most common forms of cancer worldwide. Aberrant signaling of the FGF19-FGFR4 pathway leads to HCC in mice and is hypothesized to be a driver in FGF19 amplified HCC in humans. Multiple small molecule inhibitors have been pursued as targeted therapies for HCC in recent years, including several selective FGFR4 inhibitors that are currently being evaluated in clinical trials. Herein, we report a novel series of highly selective, covalent 2-amino-6,8-dimethyl-pyrido[2,3-d]pyrimidin-7(8H)-ones that potently and selectively inhibit FGFR4 signaling through covalent modification of Cys552, which was confirmed by X-ray crystallography. Correlative target occupancy and pFGFR4 inhibition were observed in vivo, as well as tumor regression in preclinical models of orthotopic and sorafenib-resistant HCC.
Collapse
Affiliation(s)
- Haibo Liu
- Departments of Chemistry, Biology, and Biochemistry, Bristol Myers Squibb, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States
| | - Deqiang Niu
- Departments of Chemistry, Biology, and Biochemistry, Bristol Myers Squibb, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States
| | - Robert Tjin Tham Sjin
- Departments of Chemistry, Biology, and Biochemistry, Bristol Myers Squibb, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States
| | - Alex Dubrovskiy
- Departments of Chemistry, Biology, and Biochemistry, Bristol Myers Squibb, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States
| | - Zhendong Zhu
- Departments of Chemistry, Biology, and Biochemistry, Bristol Myers Squibb, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States
| | - Joseph J. McDonald
- Departments of Chemistry, Biology, and Biochemistry, Bristol Myers Squibb, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States
| | - Kelly Fahnoe
- Departments of Chemistry, Biology, and Biochemistry, Bristol Myers Squibb, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States
| | - Zhigang Wang
- Departments of Chemistry, Biology, and Biochemistry, Bristol Myers Squibb, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States
| | - Mark Munson
- Departments of Integrated Drug Discovery, DMPK, and Pharmacology, Sanofi, 153 Second Avenue, Waltham, Massachusetts 02451, United States
| | - Andrew Scholte
- Departments of Integrated Drug Discovery, DMPK, and Pharmacology, Sanofi, 153 Second Avenue, Waltham, Massachusetts 02451, United States
| | - Matthieu Barrague
- Departments of Integrated Drug Discovery, DMPK, and Pharmacology, Sanofi, 153 Second Avenue, Waltham, Massachusetts 02451, United States
| | - Maria Fitzgerald
- Departments of Integrated Drug Discovery, DMPK, and Pharmacology, Sanofi, 153 Second Avenue, Waltham, Massachusetts 02451, United States
| | - Jinyu Liu
- Departments of Integrated Drug Discovery, DMPK, and Pharmacology, Sanofi, 153 Second Avenue, Waltham, Massachusetts 02451, United States
| | - Michael Kothe
- Departments of Integrated Drug Discovery, DMPK, and Pharmacology, Sanofi, 153 Second Avenue, Waltham, Massachusetts 02451, United States
| | - Fangxian Sun
- Departments of Integrated Drug Discovery, DMPK, and Pharmacology, Sanofi, 153 Second Avenue, Waltham, Massachusetts 02451, United States
| | - Joshua Murtie
- Departments of Integrated Drug Discovery, DMPK, and Pharmacology, Sanofi, 153 Second Avenue, Waltham, Massachusetts 02451, United States
| | - Jie Ge
- Departments of Integrated Drug Discovery, DMPK, and Pharmacology, Sanofi, 153 Second Avenue, Waltham, Massachusetts 02451, United States
| | - Jennifer Rocnik
- Departments of Integrated Drug Discovery, DMPK, and Pharmacology, Sanofi, 153 Second Avenue, Waltham, Massachusetts 02451, United States
| | - Darren Harvey
- Departments of Integrated Drug Discovery, DMPK, and Pharmacology, Sanofi, 153 Second Avenue, Waltham, Massachusetts 02451, United States
| | - Beatriz Ospina
- Departments of Integrated Drug Discovery, DMPK, and Pharmacology, Sanofi, 153 Second Avenue, Waltham, Massachusetts 02451, United States
| | - Keli Perron
- Departments of Integrated Drug Discovery, DMPK, and Pharmacology, Sanofi, 153 Second Avenue, Waltham, Massachusetts 02451, United States
| | - Gang Zheng
- Departments of Integrated Drug Discovery, DMPK, and Pharmacology, Sanofi, 153 Second Avenue, Waltham, Massachusetts 02451, United States
| | - Elvis Shehu
- Departments of Integrated Drug Discovery, DMPK, and Pharmacology, Sanofi, 153 Second Avenue, Waltham, Massachusetts 02451, United States
| | - Laura Akullian D’Agostino
- Departments of Chemistry, Biology, and Biochemistry, Bristol Myers Squibb, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States
| |
Collapse
|
5
|
Mahoney CE, Pirman D, Chubukov V, Sleger T, Hayes S, Fan ZP, Allen EL, Chen Y, Huang L, Liu M, Zhang Y, McDonald G, Narayanaswamy R, Choe S, Chen Y, Gross S, Cianchetta G, Padyana AK, Murray S, Liu W, Marks KM, Murtie J, Dorsch M, Jin S, Nagaraja N, Biller SA, Roddy T, Popovici-Muller J, Smolen GA. A chemical biology screen identifies a vulnerability of neuroendocrine cancer cells to SQLE inhibition. Nat Commun 2019; 10:96. [PMID: 30626880 PMCID: PMC6327044 DOI: 10.1038/s41467-018-07959-4] [Citation(s) in RCA: 57] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2018] [Accepted: 12/04/2018] [Indexed: 12/31/2022] Open
Abstract
Aberrant metabolism of cancer cells is well appreciated, but the identification of cancer subsets with specific metabolic vulnerabilities remains challenging. We conducted a chemical biology screen and identified a subset of neuroendocrine tumors displaying a striking pattern of sensitivity to inhibition of the cholesterol biosynthetic pathway enzyme squalene epoxidase (SQLE). Using a variety of orthogonal approaches, we demonstrate that sensitivity to SQLE inhibition results not from cholesterol biosynthesis pathway inhibition, but rather surprisingly from the specific and toxic accumulation of the SQLE substrate, squalene. These findings highlight SQLE as a potential therapeutic target in a subset of neuroendocrine tumors, particularly small cell lung cancers.
Collapse
Affiliation(s)
| | - David Pirman
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA, 02139, USA
| | - Victor Chubukov
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA, 02139, USA
| | - Taryn Sleger
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA, 02139, USA
| | - Sebastian Hayes
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA, 02139, USA
| | - Zi Peng Fan
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA, 02139, USA
| | - Eric L Allen
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA, 02139, USA
| | - Ying Chen
- Shanghai ChemPartner Co. Ltd., 998 Halei Road, Pudong, 201203, Shanghai, China
| | - Lingling Huang
- Shanghai ChemPartner Co. Ltd., 998 Halei Road, Pudong, 201203, Shanghai, China
| | - Meina Liu
- Shanghai ChemPartner Co. Ltd., 998 Halei Road, Pudong, 201203, Shanghai, China
| | - Yingjia Zhang
- Shanghai ChemPartner Co. Ltd., 998 Halei Road, Pudong, 201203, Shanghai, China
| | | | | | - Sung Choe
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA, 02139, USA
| | - Yue Chen
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA, 02139, USA
| | - Stefan Gross
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA, 02139, USA
| | | | - Anil K Padyana
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA, 02139, USA
| | - Stuart Murray
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA, 02139, USA
| | - Wei Liu
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA, 02139, USA
| | - Kevin M Marks
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA, 02139, USA
| | - Joshua Murtie
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA, 02139, USA
| | - Marion Dorsch
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA, 02139, USA
| | - Shengfang Jin
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA, 02139, USA
| | | | - Scott A Biller
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA, 02139, USA
| | - Thomas Roddy
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA, 02139, USA
| | - Janeta Popovici-Muller
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA, 02139, USA
- Decibel Therapeutics, 1325 Boylston Street, Suite 500, Boston, MA, 02215, USA
| | - Gromoslaw A Smolen
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA, 02139, USA.
- Celsius Therapeutics, 215 First Street, Cambridge, MA, 02142, USA.
| |
Collapse
|
6
|
Mahoney C, Pirman D, Chubukov V, Sleger T, Padyana A, Gross S, Hayes S, Fan ZP, McDonald G, Chen Y, Murtie J, Cianchetta G, Nagaraja R, Narayanaswamy R, Choe S, Murray S, Jin S, Biller S, Roddy T, Smolen GA. Abstract 3504: A chemical biology screen identifies a unique vulnerability of neuroendocrine cancer cells to SQLE inhibition. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-3504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Numerous reports have described the differential metabolism of cancer cells as compared to their normal counterparts. However, only relatively few metabolic genes with cancer-specific mutations have been reported and the identification of cancer subsets with particular metabolic vulnerabilities remains a challenge.
To explore potential cancer-specific dependencies, we conducted a chemical biology screen utilizing a collection of small molecule inhibitors targeting diverse metabolic pathways in a large panel of cancer cell lines. A subset of neuroendocrine tumors, particularly small cell lung cancers (SCLC), displayed a striking dependence on squalene epoxygenase, SQLE, an enzyme in the cholesterol biosynthetic pathway. To develop further confidence in these findings, we have determined the first three-dimensional SQLE structure and further advanced a pharmacological toolbox for SQLE. Using these tools, we showed that the observed effects are on target and that the patterns of cellular sensitivity observed in vitro display excellent translation to in vivo xenografts studies. Interestingly, using a variety of orthogonal approaches, we demonstrated that SQLE sensitivity appears not to be related to overall inhibition of the cholesterol pathway but rather to specific and toxic accumulation of the SQLE substrate, squalene.
Collectively, these findings highlight the utility of chemical biology screens and identify SQLE as a potential therapeutic target in a subset of neuroendocrine tumors, particularly SCLC.
Citation Format: Christopher Mahoney, David Pirman, Victor Chubukov, Taryn Sleger, Anil Padyana, Stefan Gross, Sebastian Hayes, Zi Peng Fan, Gabrielle McDonald, Yu Chen, Joshua Murtie, Giovanni Cianchetta, Raj Nagaraja, Rohini Narayanaswamy, Sung Choe, Stuart Murray, Shengfang Jin, Scott Biller, Thomas Roddy, Gromoslaw A. Smolen. A chemical biology screen identifies a unique vulnerability of neuroendocrine cancer cells to SQLE inhibition [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3504.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Yu Chen
- Agios Pharmaceuticals, Cambridge, MA
| | | | | | | | | | - Sung Choe
- Agios Pharmaceuticals, Cambridge, MA
| | | | | | | | | | | |
Collapse
|
7
|
Koundinya M, Sudhalter J, Courjaud A, Lionne B, Touyer G, Bonnet L, Menguy I, Schreiber I, Perrault C, Vougier S, Benhamou B, Zhang B, He T, Gao Q, Gee P, Simard D, Castaldi MP, Tomlinson R, Reiling S, Barrague M, Newcombe R, Cao H, Wang Y, Sun F, Murtie J, Munson M, Yang E, Harper D, Bouaboula M, Pollard J, Grepin C, Garcia-Echeverria C, Cheng H, Adrian F, Winter C, Licht S, Cornella-Taracido I, Arrebola R, Morris A. Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers. Cell Chem Biol 2018; 25:705-717.e11. [PMID: 29628435 DOI: 10.1016/j.chembiol.2018.03.005] [Citation(s) in RCA: 66] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2016] [Revised: 12/29/2017] [Accepted: 03/08/2018] [Indexed: 12/13/2022]
Abstract
Activating KRAS mutations are major oncogenic drivers in multiple tumor types. Synthetic lethal screens have previously been used to identify targets critical for the survival of KRAS mutant cells, but their application to drug discovery has proven challenging, possibly due in part to a failure of monolayer cultures to model tumor biology. Here, we report the results of a high-throughput synthetic lethal screen for small molecules that selectively inhibit the growth of KRAS mutant cell lines in soft agar. Chemoproteomic profiling identifies the target of the most KRAS-selective chemical series as dihydroorotate dehydrogenase (DHODH). DHODH inhibition is shown to perturb multiple metabolic pathways. In vivo preclinical studies demonstrate strong antitumor activity upon DHODH inhibition in a pancreatic tumor xenograft model.
Collapse
Affiliation(s)
| | - Judith Sudhalter
- Cancer Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | | | | | | | - Luc Bonnet
- LGCR-LIT, Sanofi, Vitry-Sur-Seine 94400, France
| | | | | | | | | | | | - Bailin Zhang
- Biochemistry, Bioanalytics, and Chemical Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Timothy He
- Biochemistry, Bioanalytics, and Chemical Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Qiang Gao
- Biochemistry, Bioanalytics, and Chemical Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Patricia Gee
- Biochemistry, Bioanalytics, and Chemical Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Daniel Simard
- Biochemistry, Bioanalytics, and Chemical Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA; Chemistry, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | | | | | - Stephan Reiling
- LGCR-SDI, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | | | - Richard Newcombe
- Cancer Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Hui Cao
- TEM-BioInformatics, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Yanjun Wang
- In Vivo Pharmacology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Fangxian Sun
- In Vivo Pharmacology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Joshua Murtie
- In Vivo Pharmacology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Mark Munson
- LGCR, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Eric Yang
- TEM-BioInformatics, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - David Harper
- Cancer Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Monsif Bouaboula
- Cancer Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Jack Pollard
- TEM-BioInformatics, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | | | - Carlos Garcia-Echeverria
- Biochemistry, Bioanalytics, and Chemical Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Hong Cheng
- Biochemistry, Bioanalytics, and Chemical Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | - Francisco Adrian
- Cancer Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA
| | | | - Stuart Licht
- Biochemistry, Bioanalytics, and Chemical Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
| | | | | | - Aaron Morris
- Cancer Biology, Oncology Division, Sanofi, Cambridge, MA 02138, USA.
| |
Collapse
|
8
|
Allen EL, Ulanet DB, Pirman D, Mahoney CE, Coco J, Si Y, Chen Y, Huang L, Ren J, Choe S, Clasquin MF, Artin E, Fan ZP, Cianchetta G, Murtie J, Dorsch M, Jin S, Smolen GA. Differential Aspartate Usage Identifies a Subset of Cancer Cells Particularly Dependent on OGDH. Cell Rep 2017; 17:876-890. [PMID: 27732861 DOI: 10.1016/j.celrep.2016.09.052] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2016] [Revised: 08/18/2016] [Accepted: 09/16/2016] [Indexed: 12/16/2022] Open
Abstract
Although aberrant metabolism in tumors has been well described, the identification of cancer subsets with particular metabolic vulnerabilities has remained challenging. Here, we conducted an siRNA screen focusing on enzymes involved in the tricarboxylic acid (TCA) cycle and uncovered a striking range of cancer cell dependencies on OGDH, the E1 subunit of the alpha-ketoglutarate dehydrogenase complex. Using an integrative metabolomics approach, we identified differential aspartate utilization, via the malate-aspartate shuttle, as a predictor of whether OGDH is required for proliferation in 3D culture assays and for the growth of xenograft tumors. These findings highlight an anaplerotic role of aspartate and, more broadly, suggest that differential nutrient utilization patterns can identify subsets of cancers with distinct metabolic dependencies for potential pharmacological intervention.
Collapse
Affiliation(s)
- Eric L Allen
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | | | - David Pirman
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | | | - John Coco
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | - Yaguang Si
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | - Ying Chen
- Shanghai ChemPartner Co. Ltd., 998 Halei Road, Pudong, 201203 Shanghai, China
| | - Lingling Huang
- Shanghai ChemPartner Co. Ltd., 998 Halei Road, Pudong, 201203 Shanghai, China
| | - Jinmin Ren
- Shanghai ChemPartner Co. Ltd., 998 Halei Road, Pudong, 201203 Shanghai, China
| | - Sung Choe
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | | | - Erin Artin
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | - Zi Peng Fan
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | | | - Joshua Murtie
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | - Marion Dorsch
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | - Shengfang Jin
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | | |
Collapse
|
9
|
Lampa M, Arlt H, He T, Ospina B, Reeves J, Zhang B, Murtie J, Deng G, Barberis C, Hoffmann D, Cheng H, Pollard J, Winter C, Richon V, Garcia-Escheverria C, Adrian F, Wiederschain D, Srinivasan L. Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition. PLoS One 2017; 12:e0185092. [PMID: 28950000 PMCID: PMC5614427 DOI: 10.1371/journal.pone.0185092] [Citation(s) in RCA: 99] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2017] [Accepted: 09/06/2017] [Indexed: 12/23/2022] Open
Abstract
Tumor cells display fundamental changes in metabolism and nutrient uptake in order to utilize additional nutrient sources to meet their enhanced bioenergetic requirements. Glutamine (Gln) is one such nutrient that is rapidly taken up by tumor cells to fulfill this increased metabolic demand. A vital step in the catabolism of glutamine is its conversion to glutamate by the mitochondrial enzyme glutaminase (GLS). This study has identified GLS a potential therapeutic target in breast cancer, specifically in the basal subtype that exhibits a deregulated glutaminolysis pathway. Using inducible shRNA mediated gene knockdown, we discovered that loss of GLS function in triple-negative breast cancer (TNBC) cell lines with a deregulated glutaminolysis pathway led to profound tumor growth inhibition in vitro and in vivo. GLS knockdown had no effect on growth and metabolite levels in non-TNBC cell lines. We rescued the anti-tumor effect of GLS knockdown using shRNA resistant cDNAs encoding both GLS isoforms and by addition of an α-ketoglutarate (αKG) analog thus confirming the critical role of GLS in TNBC. Pharmacological inhibition of GLS with the small molecule inhibitor CB-839 reduced cell growth and led to a decrease in mammalian target of rapamycin (mTOR) activity and an increase in the stress response pathway driven by activating transcription factor 4 (ATF4). Finally, we found that GLS inhibition synergizes with mTOR inhibition, which introduces the possibility of a novel therapeutic strategy for TNBC. Our study revealed that GLS is essential for the survival of TNBC with a deregulated glutaminolysis pathway. The synergistic activity of GLS and mTOR inhibitors in TNBC cell lines suggests therapeutic potential of this combination for the treatment of vulnerable subpopulations of TNBC.
Collapse
Affiliation(s)
- Michael Lampa
- Oncology, Sanofi, Cambridge, MA, United States of America
| | - Heike Arlt
- Oncology, Sanofi, Cambridge, MA, United States of America
| | - Timothy He
- Oncology, Sanofi, Cambridge, MA, United States of America
| | - Beatriz Ospina
- Oncology, Sanofi, Cambridge, MA, United States of America
| | - Jason Reeves
- Oncology, Sanofi, Cambridge, MA, United States of America
| | - Bailin Zhang
- Oncology, Sanofi, Cambridge, MA, United States of America
| | - Joshua Murtie
- Oncology, Sanofi, Cambridge, MA, United States of America
| | - Gejing Deng
- Oncology, Sanofi, Cambridge, MA, United States of America
| | - Claude Barberis
- Integrated Drug Discovery Platform, Sanofi, Waltham, MA, United States of America
| | | | - Hong Cheng
- Oncology, Sanofi, Cambridge, MA, United States of America
| | - Jack Pollard
- Oncology, Sanofi, Cambridge, MA, United States of America
| | | | | | | | | | | | | |
Collapse
|
10
|
Marjon K, Cameron MJ, Quang P, Clasquin MF, Mandley E, Kunii K, McVay M, Choe S, Kernytsky A, Gross S, Konteatis Z, Murtie J, Blake ML, Travins J, Dorsch M, Biller SA, Marks KM. MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis. Cell Rep 2016; 15:574-587. [PMID: 27068473 DOI: 10.1016/j.celrep.2016.03.043] [Citation(s) in RCA: 233] [Impact Index Per Article: 29.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2015] [Revised: 02/08/2016] [Accepted: 03/10/2016] [Indexed: 12/31/2022] Open
Abstract
Homozygous deletions of p16/CDKN2A are prevalent in cancer, and these mutations commonly involve co-deletion of adjacent genes, including methylthioadenosine phosphorylase (MTAP). Here, we used shRNA screening and identified the metabolic enzyme, methionine adenosyltransferase II alpha (MAT2A), and the arginine methyltransferase, PRMT5, as vulnerable enzymes in cells with MTAP deletion. Metabolomic and biochemical studies revealed a mechanistic basis for this synthetic lethality. The MTAP substrate methylthioadenosine (MTA) accumulates upon MTAP loss. Biochemical profiling of a methyltransferase enzyme panel revealed that MTA is a potent and selective inhibitor of PRMT5. MTAP-deleted cells have reduced PRMT5 methylation activity and increased sensitivity to PRMT5 depletion. MAT2A produces the PRMT5 substrate S-adenosylmethionine (SAM), and MAT2A depletion reduces growth and PRMT5 methylation activity selectively in MTAP-deleted cells. Furthermore, this vulnerability extends to PRMT5 co-complex proteins such as RIOK1. Thus, the unique biochemical features of PRMT5 create an axis of targets vulnerable in CDKN2A/MTAP-deleted cancers.
Collapse
Affiliation(s)
- Katya Marjon
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | | | - Phong Quang
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | | | - Everton Mandley
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | - Kaiko Kunii
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | - Michael McVay
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | - Sung Choe
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | - Andrew Kernytsky
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | - Stefan Gross
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | - Zenon Konteatis
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | - Joshua Murtie
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | - Michelle L Blake
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | - Jeremy Travins
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | - Marion Dorsch
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | - Scott A Biller
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA
| | - Kevin M Marks
- Agios Pharmaceuticals, 88 Sidney Street, Cambridge, MA 02139, USA.
| |
Collapse
|
11
|
Ding Z, Lennon A, Perron K, Harper D, Su H, Wolfram M, Murtie J, Licht S, Pinckney J, Simonds-Mannes H, Bishop K, Gavigan JA, Bangari D, Magnay M, Weber W, Reczek D, Brondyk W, Drewett V, Trombe M, Hoffmann D, Baffa R, Silver S, Richon V, Winter C, Reddy V, Gregory RC. Abstract 5448: PTK7 as a potential therapeutic target in ovarian cancer. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-5448] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The identification of proteins that selectively discriminate between tumor cells and normal adult cells allows for the specific targeting of diseased cells with antibody therapeutics. One such recently identified protein, PTK7, is an onco-fetal membrane protein which exhibits limited expression and function in adults. PTK7 was identified as a member of the RTK super family but lacks a functional kinase domain. Normally, PTK7 is expressed early in development and its loss is associated with severe defects in neural tube closure and sensory hair cell bundle formation. Functionally, little is known about the signaling involving PTK7, but it has been linked to both the canonical and noncanonical WNT pathways. Recently, PTK7 expression has been shown to be upregulated in a number of cancers including: ovarian, melanoma, leukemia, lung, pancreatic, colon, renal and breast. In vitro and in vivo studies support a role in regulating angiogenesis, invasion & survival. To further validate PTK7 as a potential cancer target that may be required for tumor maintenance and progression, we analyzed the expression of PTK7 in normal and tumor samples, and validated an in vitro and in vivo role of PTK7 on cell growth in ovarian cancer cell lines using both genetic tools and polyclonal antibodies. Silencing PTK7 with stably expressed inducible shRNAs is shown to inhibit the growth of ovarian cancer cell lines in vitro and to lead to delayed tumor growth upon PTK7 knockdown in murine tumor xenograft models. Further supporting the role of PTK7 as a potential antibody target, polyclonal antibodies to PTK7 are shown to inhibit the growth of SKOV3 and OVCAR8 cells in vitro. Although 4 human antibodies derived from phage display failed to inhibit in vitro cell growth, these results suggest that functionally blocking PTK7 may lead to the inhibition of ovarian tumor growth and is a potential target for antibody therapies.
Citation Format: Zhihu Ding, Amanda Lennon, Keli Perron, David Harper, Hui Su, Meredith Wolfram, Joshua Murtie, Stuart Licht, Jason Pinckney, Helene Simonds-Mannes, Kimberly Bishop, Julie-Ann Gavigan, Dinesh Bangari, Maureen Magnay, William Weber, David Reczek, William Brondyk, Vicky Drewett, Marc Trombe, Dietmar Hoffmann, Raffaele Baffa, Serena Silver, Victoria Richon, Christopher Winter, Venkat Reddy, Richard C. Gregory. PTK7 as a potential therapeutic target in ovarian cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 5448. doi:10.1158/1538-7445.AM2014-5448
Collapse
|
12
|
Garner AP, Bialucha CU, Sprague ER, Garrett JT, Sheng Q, Li S, Sineshchekova O, Saxena P, Sutton CR, Chen D, Chen Y, Wang H, Liang J, Das R, Mosher R, Gu J, Huang A, Haubst N, Zehetmeier C, Haberl M, Elis W, Kunz C, Heidt AB, Herlihy K, Murtie J, Schuller A, Arteaga CL, Sellers WR, Ettenberg SA. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Cancer Res 2013; 73:6024-35. [PMID: 23928993 DOI: 10.1158/0008-5472.can-13-1198] [Citation(s) in RCA: 98] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
HER2/HER3 dimerization resulting from overexpression of HER2 or neuregulin (NRG1) in cancer leads to HER3-mediated oncogenic activation of phosphoinositide 3-kinase (PI3K) signaling. Although ligand-blocking HER3 antibodies inhibit NRG1-driven tumor growth, they are ineffective against HER2-driven tumor growth because HER2 activates HER3 in a ligand-independent manner. In this study, we describe a novel HER3 monoclonal antibody (LJM716) that can neutralize multiple modes of HER3 activation, making it a superior candidate for clinical translation as a therapeutic candidate. LJM716 was a potent inhibitor of HER3/AKT phosphorylation and proliferation in HER2-amplified and NRG1-expressing cancer cells, and it displayed single-agent efficacy in tumor xenograft models. Combining LJM716 with agents that target HER2 or EGFR produced synergistic antitumor activity in vitro and in vivo. In particular, combining LJM716 with trastuzumab produced a more potent inhibition of signaling and cell proliferation than trastuzumab/pertuzumab combinations with similar activity in vivo. To elucidate its mechanism of action, we solved the structure of LJM716 bound to HER3, finding that LJM716 bound to an epitope, within domains 2 and 4, that traps HER3 in an inactive conformation. Taken together, our findings establish that LJM716 possesses a novel mechanism of action that, in combination with HER2- or EGFR-targeted agents, may leverage their clinical efficacy in ErbB-driven cancers.
Collapse
Affiliation(s)
- Andrew P Garner
- Authors' Affiliations: Novartis Institutes for Biomedical Research, Cambridge, Massachusetts; Departments of Medicine and Cancer Biology; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; MorphoSys AG, Martinsried, Germany; and Genomics Institute of the Novartis Research Foundation, San Diego, California
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Zhang JX, Murtie J, Iartchouk O, Cao H, Shapiro G, Li Z, Wang H, Ding Z, Zhang YA, Light M, Hoffman D, Cindhuchao M, Jani S, Newcombe R, Bric-Furlong E, Wu B, Virone-Oddos A, Reiling S, Theihaber J, Lengauer C, Pollard J, Watters J, Silver S, Reddy V. Abstract 3135: In vitro and in vivo synthetic lethal screens to identify novel targets in the context of PTEN deficiency. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-3135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Functional genomic screens have been employed by many groups to identify novel targets for cancer therapeutics. However, translation of these data sets into new drug discovery programs has proved challenging, in part due to difficulties in obtaining strong on-target knockdown, coupled with misleading off-target effects. Most commercially available pooled shRNA screening libraries provide 5-6 shRNAs per gene, with little knowledge of knock-down efficiency. In an effort to overcome these issues, we designed a custom shRNA library targeting 580 human genes, including key nodes in signal transduction pathways and genes of interest for oncology drug development. This pathway-centric design allows us to determine critical pathways for cancer cell growth in addition to individual gene phenotypes. For each gene, we have total of 11 shRNAs, a subset of which have been previously shown high efficiency knock-down. In particular, we emphasized genes where tool or lead compounds were available for rapid follow-up. Both in size and scope, this library was designed to quickly identify important signaling pathways that are essential on their own or when perturbed in the presence of small molecule drugs in our pipeline.
With this focused library, we performed functional genomic shRNA screens in PTEN mutant or null lines across cancer types in vitro, including four cell lines that are PTEN deficient (UACC62, MDA-MB-468, U87-MG and PC3), and one cell line, (HCT-116) that is PTEN wild type. Meanwhile, we performed in vivo screens with PC3 cells. To identify hits from our screens, we used an internally developed algorithm, c-FOLD, to calculate p-value and fold changes for each shRNA. As confirmation that our library and methods can identify essential genes in a context specific manner, we observe BRAF as the top essential gene hit in the cell line which contains an activated BRAF allele, UACC62, but not in other lines tested. We then examined the concordance of hits in our in vitro and in vivo experiments with PC3 cells. In general, individual shRNAs were highly correlated between in vitro and in vivo assays, but a subset is specific to one setting, and may present particularly interesting targets.
To discover synthetic lethal partners to PTEN deficiency, we required that a gene is essential in all four PTEN deficient lines in vitro, as well as in PC3 in vivo, but not essential in HCT-116. Among the top hits are multiple shRNAs against ENTPD5, an ER enzyme hydrolyzing UDP to UMP. In addition, using our pathway approach, we identified components in JNK pathways as synthetic lethal partners to PTEN deficiency. The results obtained from these studies established a strong platform for in vivo and in vitro identification of novel targets and novel combination partners. These approaches can also be integrated with other Omics data, such as mutation and expression, to ultimately find promising targets to develop novel cancer therapeutics.
Citation Format: Jing-xin Zhang, Joshua Murtie, Oleg Iartchouk, Hui Cao, Gary Shapiro, Zhifang Li, Hongyun Wang, Zhihu Ding, Yu-an Zhang, Madelyn Light, Dietmar Hoffman, May Cindhuchao, Saurin Jani, Richard Newcombe, Eva Bric-Furlong, Bin Wu, Angela Virone-Oddos, Stephan Reiling, Joachim Theihaber, Christoph Lengauer, Jack Pollard, James Watters, Serena Silver, Venkat Reddy. In vitro and in vivo synthetic lethal screens to identify novel targets in the context of PTEN deficiency. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3135. doi:10.1158/1538-7445.AM2013-3135
Collapse
|
14
|
Garner A, Sheng Q, Bialucha U, Chen D, Chen Y, Das R, Elis W, Heidt A, Kunz C, Li S, Liang J, Murtie J, Saxena P, Schuller A, Sineshchekova O, Sprague E, Wang HQ, Huang A, Ettenberg S. Abstract 2733: LJM716: an anti-HER3 antibody that inhibits both HER2 and NRG driven tumor growth by trapping HER3 in the inactive conformation. Cancer Res 2012. [DOI: 10.1158/1538-7445.am2012-2733] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
HER3 (ErbB3) is a member of the ErbB family of receptor tyrosine kinases (RTK). Inappropriate HER2/ HER3 dimerization as a result of HER2 or neuregulin (NRG) over-expression in cancer results in HER3 mediated activation of PI3K signaling. Consequently, HER3 is a mediator of oncogenic transformation. Although, ligand blocking HER3 antibodies inhibit growth of neuregulin driven xenograft models they are ineffective in models of HER2 amplified cancer as HER2 mediated activation of HER3 occurs in a ligand- independent manner. LJM716 is a high affinity HER3- targeted antibody selected from a Human Combinatorial Antibody Library (HuCAL) specifically for its ability to neutralize multiple modes of HER3 activation. LJM716 is a potent inhibitor of HER3/ AKT phosphorylation and proliferation in a range of HER2 amplified and NRG expressing cell lines in vitro. LJM716 induced tumor regression in Fadu (NRG expressing, HNSCC) tumor xenografts and significant tumor growth inhibition (>80%) in a variety of xenograft models including BT474 (HER2 amplified breast). Furthermore, the combination of LJM716 with trastuzumab, cetuximab or PI3K- targeted agents was synergistic in a panel of in vitro cell lines while the in vivo combination of LJM716 with trastuzumab or erlotinib was efficacious in BT474 and L3.3 (pancreatic) tumor xenografts respectively. To further understand the mechanism by which LJM716 inhibits multiple modes of HER3 activation we solved the crystal structure of LJM716 bound to the HER3 extra-cellular domain. This data revealed that LJM716 binds to a novel conformational epitope contained within domains 2 and 4 and appears to trap HER3 in the inactive conformation. Interestingly, LJM716 does not block NRG binding to HER3 nor does it affect the binding affinity of the HER3/ NRG interaction. LJM716 therefore possesses a novel mechanism of action; it prevents the structural rearrangements required for HER3 activation induced by either HER2 or NRG. Thus LJM716 is the first HER3 antibody to display efficacy in both HER2 and ligand driven xenograft models. Based on preclinical data, combining LJM716 with either trastuzumab, cetuximab or PI3K- targeted agents may lead to greater and more sustained clinical efficacy in ErbB driven cancers.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2733. doi:1538-7445.AM2012-2733
Collapse
Affiliation(s)
- Andrew Garner
- 1Novartis Institutes for Biomedical Research, Cambridge, MA
| | - Qing Sheng
- 1Novartis Institutes for Biomedical Research, Cambridge, MA
| | - Uli Bialucha
- 1Novartis Institutes for Biomedical Research, Cambridge, MA
| | - Dongshu Chen
- 1Novartis Institutes for Biomedical Research, Cambridge, MA
| | - Yan Chen
- 1Novartis Institutes for Biomedical Research, Cambridge, MA
| | - Rita Das
- 1Novartis Institutes for Biomedical Research, Cambridge, MA
| | | | - Analeah Heidt
- 3Genomics Institute of the Novartis Research Foundation, San Diego, CA
| | | | - Sharon Li
- 1Novartis Institutes for Biomedical Research, Cambridge, MA
| | - Jinsheng Liang
- 1Novartis Institutes for Biomedical Research, Cambridge, MA
| | | | - Parmita Saxena
- 1Novartis Institutes for Biomedical Research, Cambridge, MA
| | - Alwin Schuller
- 1Novartis Institutes for Biomedical Research, Cambridge, MA
| | | | | | - Hui Qin Wang
- 1Novartis Institutes for Biomedical Research, Cambridge, MA
| | - Alan Huang
- 1Novartis Institutes for Biomedical Research, Cambridge, MA
| | - Seth Ettenberg
- 1Novartis Institutes for Biomedical Research, Cambridge, MA
| |
Collapse
|
15
|
Garner AP, Bialucha CU, Chen D, Elis W, Kunz C, Li S, Murtie J, Saxena P, Sineshchekova O, Sprague E, Ettenberg S. S2-5: An Anti-HER3 Antibody That Stabilizes the Inactive Conformation Inhibits Both HER2 and Ligand Driven Tumor Growth. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-s2-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: HER3 (ErbB3) is a member of the ErbB family of receptor tyrosine kinases (RTK). In normal physiology, ligands (e.g. neuregulin) activate HER3 by promoting dimerization with other RTK's such as HER2 (ErbB2). Inappropriate HER2/HER3 dimerization as a result of HER2 over-expression in cancer results in HER3 mediated activation of the oncogenic PI3K pathway. The HER2− targeted antibody trastuzumab inefficiently inhibits HER2 mediated HER3 activation allowing persistent HER3 signaling that is speculated to limit clinical responses. Consequently, combination of a HER3- targeted agent with trastuzumab may be of clinical benefit. Furthermore, ectopic HER3 activation has recently been implicated in the relief of a feedback loop induced by PI3K inhibitors that may perhaps limit their efficacy in HER2 driven tumors. Since HER3 activation in HER2 driven cancers occurs in a ligand- independent manner, antibodies that primarily inhibit ligand- induced HER3 activation are largely inactive in HER2 driven xenograft models.
Results: H3F15, a high affinity (26pM) HER3- targeted fully human IgG1 antibody was selected from the Human Combinatorial Antibody Library (HuCAL) using phage display technology. In a broad range of HER2 amplified breast and gastric cell lines, H3F15 displayed potent inhibition (IC50 <1nM) of HER3/AKT phosphorylation and proliferation. Interestingly, H3F15 also effectively inhibited neuregulin stimulated HER3 phosphorylation and downstream signaling in MCF7 cells indicating that H3F15 inhibits multiple modes of HER3 activation. Determining the H3F15/HER3 crystal structure revealed that H3F15 binds a novel conformational epitope that traps HER3 in the inactive conformation thus preventing its activation by either HER2 or neuregulin. In vivo testing of H3F15 using xenograft tumor models driven by either HER2 (BT474) or HER3 ligands (BxPC3) confirmed that single agent H3F15 (20mg/kg) significantly inhibited tumor growth (83 and 77% inhibition respectively). Furthermore, combinations of H3F15 with either trastuzumab or PI3K- targeted agents were synergistic in a panel of HER2 driven cell lines whilst the in vivo combination of H3F15 (20mg/kg) with trastuzumab (1mg/kg) was sufficient to induce tumor regression.
Discussion: H3F15 is a HER3- targeted antagonist IgG1 that stabilizes the inactive form of HER3. This novel mechanism of action enables H3F15 to uniquely inhibit both ligand-induced and HER2−mediated activation of HER3. Thus H3F15 is the first HER3 antibody to display single-agent efficacy in both HER2 and ligand driven xenograft models whilst also inducing tumor regressions in combination with trastuzumab. Based on preclinical data, combining H3F15 with either trastuzumab or PI3K- targeted agents fully inhibits the HER2/HER3 signaling pathway, which may lead to greater and more sustained clinical efficacy in HER2 driven cancers.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr S2-5.
Collapse
Affiliation(s)
- AP Garner
- 1Novartis Institutes for Biomedical Research, Cambridge, MA; Morphosys AG, Munich, Germany; Sanofi-Aventis, Cambridge, MA
| | - CU Bialucha
- 1Novartis Institutes for Biomedical Research, Cambridge, MA; Morphosys AG, Munich, Germany; Sanofi-Aventis, Cambridge, MA
| | - D Chen
- 1Novartis Institutes for Biomedical Research, Cambridge, MA; Morphosys AG, Munich, Germany; Sanofi-Aventis, Cambridge, MA
| | - W Elis
- 1Novartis Institutes for Biomedical Research, Cambridge, MA; Morphosys AG, Munich, Germany; Sanofi-Aventis, Cambridge, MA
| | - C Kunz
- 1Novartis Institutes for Biomedical Research, Cambridge, MA; Morphosys AG, Munich, Germany; Sanofi-Aventis, Cambridge, MA
| | - S Li
- 1Novartis Institutes for Biomedical Research, Cambridge, MA; Morphosys AG, Munich, Germany; Sanofi-Aventis, Cambridge, MA
| | - J Murtie
- 1Novartis Institutes for Biomedical Research, Cambridge, MA; Morphosys AG, Munich, Germany; Sanofi-Aventis, Cambridge, MA
| | - P Saxena
- 1Novartis Institutes for Biomedical Research, Cambridge, MA; Morphosys AG, Munich, Germany; Sanofi-Aventis, Cambridge, MA
| | - O Sineshchekova
- 1Novartis Institutes for Biomedical Research, Cambridge, MA; Morphosys AG, Munich, Germany; Sanofi-Aventis, Cambridge, MA
| | - E Sprague
- 1Novartis Institutes for Biomedical Research, Cambridge, MA; Morphosys AG, Munich, Germany; Sanofi-Aventis, Cambridge, MA
| | - S Ettenberg
- 1Novartis Institutes for Biomedical Research, Cambridge, MA; Morphosys AG, Munich, Germany; Sanofi-Aventis, Cambridge, MA
| |
Collapse
|
16
|
Jagani Z, Mora-Blanco EL, Sansam CG, McKenna ES, Wilson B, Chen D, Klekota J, Tamayo P, Nguyen PTL, Tolstorukov M, Park PJ, Cho YJ, Hsiao K, Buonamici S, Pomeroy SL, Mesirov JP, Ruffner H, Bouwmeester T, Luchansky SJ, Murtie J, Kelleher JF, Warmuth M, Sellers WR, Roberts CWM, Dorsch M. Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nat Med 2010; 16:1429-33. [PMID: 21076395 DOI: 10.1038/nm.2251] [Citation(s) in RCA: 187] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2010] [Accepted: 09/30/2010] [Indexed: 01/18/2023]
Abstract
Aberrant activation of the Hedgehog (Hh) pathway can drive tumorigenesis. To investigate the mechanism by which glioma-associated oncogene family zinc finger-1 (GLI1), a crucial effector of Hh signaling, regulates Hh pathway activation, we searched for GLI1-interacting proteins. We report that the chromatin remodeling protein SNF5 (encoded by SMARCB1, hereafter called SNF5), which is inactivated in human malignant rhabdoid tumors (MRTs), interacts with GLI1. We show that Snf5 localizes to Gli1-regulated promoters and that loss of Snf5 leads to activation of the Hh-Gli pathway. Conversely, re-expression of SNF5 in MRT cells represses GLI1. Consistent with this, we show the presence of a Hh-Gli-activated gene expression profile in primary MRTs and show that GLI1 drives the growth of SNF5-deficient MRT cells in vitro and in vivo. Therefore, our studies reveal that SNF5 is a key mediator of Hh signaling and that aberrant activation of GLI1 is a previously undescribed targetable mechanism contributing to the growth of MRT cells.
Collapse
Affiliation(s)
- Zainab Jagani
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Gómez-Casati ME, Murtie J, Taylor B, Corfas G. Cell-specific inducible gene recombination in postnatal inner ear supporting cells and glia. J Assoc Res Otolaryngol 2009; 11:19-26. [PMID: 19820996 DOI: 10.1007/s10162-009-0191-x] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2009] [Accepted: 09/21/2009] [Indexed: 12/24/2022] Open
Abstract
Recent studies indicate that supporting cells play important roles in inner ear development, function, and regeneration after injury, but the molecular mechanisms underlying these processes remain poorly understood. Inducible cell-specific gene recombination in supporting cells could be a powerful tool to study the roles of specific molecules in these cells. Here we tested the feasibility, effectiveness, and cell specificity of inducible Cre-mediated gene recombination in the postnatal inner ear using mice that express an inducible form of Cre (CreER(T)) under the transcriptional control of the proteolipid protein (PLP) promoter. We assessed the pattern of tamoxifen-induced gene recombination in the inner ear using the ROSA26-LacZ reporter line, in which the beta-galactosidase gene is expressed only after Cre-mediated excision of a loxP-flanked stop cassette. Recombination was detected in cochlear inner phalangeal cells, supporting cells surrounding hair cells in vestibular maculae and cristae. Recombination also occurred in Schwann cells. We also found that this CreER(T) line can be used to increase and decrease the levels of expression of a trophic factor, brain-derived neurotrophic factor, specifically in supporting cells. These results show that PLP/CreER(T) mice are a powerful tool to dissect gene function in inner ear supporting cells.
Collapse
Affiliation(s)
- María Eugenia Gómez-Casati
- F.M. Kirby Neurobiology Center, Children's Hospital Boston, 3 Blackfan Circle, CLS Room 12256, Boston, MA 02115, USA
| | | | | | | |
Collapse
|
18
|
Sardi SP, Murtie J, Koirala S, Patten BA, Corfas G. Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain. Cell 2006; 127:185-97. [PMID: 17018285 DOI: 10.1016/j.cell.2006.07.037] [Citation(s) in RCA: 258] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2005] [Revised: 05/12/2006] [Accepted: 07/06/2006] [Indexed: 11/20/2022]
Abstract
Embryonic multipotent neural precursors are exposed to extracellular signals instructing them to adopt different fates, neuronal or glial. However, the mechanisms by which precursors integrate these signals to make timely fate choices remained undefined. Here we show that direct nuclear signaling by a receptor tyrosine kinase inhibits the responses of precursors to astrocyte differentiation factors while maintaining their neurogenic potential. Upon neuregulin-induced activation and presenilin-dependent cleavage of ErbB4, the receptor's intracellular domain forms a complex with TAB2 and the corepressor N-CoR. This complex undergoes nuclear translocation and binds promoters of astrocytic genes, repressing their expression. Consistent with this observation, astrogenesis occurs precociously in ErbB4 knockout mice. Our studies define how presenilin-dependent nuclear signaling by a receptor tyrosine kinase directly regulates gene transcription and cell fate. This pathway could be of importance for neural stem cell biology and for understanding the pathogenesis of Alzheimer's disease.
Collapse
Affiliation(s)
- S Pablo Sardi
- Neurobiology Program and Department of Neurology, Children's Hospital and Harvard Medical School, 300 Longwood Avenue, Boston, MA, 02115, USA
| | | | | | | | | |
Collapse
|
19
|
Eidelman O, Srivastava M, Zhang J, Leighton X, Murtie J, Jozwik C, Jacobson K, Weinstein DL, Metcalf EL, Pollard HB. Control of the proinflammatory state in cystic fibrosis lung epithelial cells by genes from the TNF-alphaR/NFkappaB pathway. Mol Med 2001; 7:523-34. [PMID: 11591888 PMCID: PMC1950060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/21/2023] Open
Abstract
BACKGROUND Cystic fibrosis (CF) is the most common, lethal autosomal recessive disease affecting children in the United States and Europe. Extensive work is being performed to develop both gene and drug therapies. The principal mutation causing CF is in the CFTR gene ([Delta F508]CFTR). This mutation causes the mutant protein to traffic poorly to the plasma membrane, and degrades CFTR chloride channel activity. CPX, a candidate drug for CF, binds to mutant CFTR and corrects the trafficking deficit. CPX also activates mutant CFTR chloride channel activity. CF airways are phenotypically inundated by inflammatory signals, primarily contributed by sustained secretion of the proinflammatory cytokine interleukin 8 (IL-8) from mutant CFTR airway epithelial cells. IL-8 production is controlled by genes from the TNF-alphaR/NFkappaB pathway, and it is possible that the CF phenotype is due to dysfunction of genes from this pathway. In addition, because drug therapy with CPX and gene therapy with CFTR have the same common endpoint of raising the levels of CFTR, we have hypothesized that either approach should have a common genomic endpoint. MATERIALS AND METHODS To test this hypothesis, we studied IL-8 secretion and global gene expression in IB-3 CF lung epithelial cells. The cells were treated by either gene therapy with wild-type CFTR, or by pharmacotherapy with the CFTR-surrogate drug CPX. CF cells, treated with either CFTR or CPX, were also exposed to Pseudomonas aeruginosa, a common chronic pathogen in CF patients. cDNA microarrays were used to assess global gene expression under the different conditions. A novel bioinformatic algorithm (GENESAVER) was developed to identify genes whose expression paralleled secretion of IL-8. RESULTS We report here that IB3 CF cells secrete massive levels of IL-8. However, both gene therapy with CFTR and drug therapy with CPX substantially suppress IL-8 secretion. Nonetheless, both gene and drug therapy allow the CF cells to respond with physiologic secretion of IL-8 when the cells are exposed to P. aeruginosa. Thus, neither CFTR nor CPX acts as a nonspecific suppressor of IL-8 secretion from CF cells. Consistently, pharmacogenomic analysis indicates that CF cells treated with CPX greatly resemble CF cells treated with CFTR by gene therapy. Additionally, the same result obtains in the presence of P. aeruginosa. Classical hierarchical cluster analysis, based on similarity of global gene expression, also supports this conclusion. The GENESAVER algorithm, using the IL-8 secretion level as a physiologic variable, identifies a subset of genes from the TNF-alphaR/NFkappaB pathway that is expressed in phase with IL-8 secretion from CF epithelial cells. Certain other genes, previously known to be positively associated with CF, also fall into this category. Identified genes known to code for known inhibitors are expressed inversely, out of phase with IL-8 secretion. CONCLUSIONS Wild-type CFTR and CPX both suppress proinflammatory IL-8 secretion from CF epithelial cells. The mechanism, as defined by pharmacogenomic analysis, involves identified genes from the TNF-alphaR/NFkappaB pathway. The close relationship between IL-8 secretion and genes from the TNF-alphaR/NFkappaB pathway suggests that molecular or pharmaceutical targeting of these novel genes may have strategic use in the development of new therapies for CF. From the perspective of global gene expression, both gene and drug therapy have similar genomic consequences. This is the first example showing equivalence of gene and drug therapy in CF, and suggests that a gene therapy-defined endpoint may prove to be a powerful paradigm for CF drug discovery. Finally, because the GENESAVER algorithm is capable of isolating disease-relevant genes in a hypothesis-driven manner without recourse to any a priori knowledge about the system, this new algorithm may also prove useful in applications to other genetic diseases.
Collapse
Affiliation(s)
- O Eidelman
- Department of Anatomy, Institute of Molecular Medicine F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|